Lexeo Therapeutics, Financials
| LXEO Stock | 4.44 0.35 8.56% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.24 | 5.5205 |
|
|
The financial analysis of Lexeo Therapeutics, is a critical element in measuring its lifeblood. Investors should not minimize Lexeo Therapeutics,'s ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Lexeo | Select Account or Indicator |
Lexeo Therapeutics, Stock Summary
Lexeo Therapeutics, competes with Neogen, Regeneron Pharmaceuticals, Griffon, Tyson Foods, and Inhibrx. Lexeo Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US52886X1072 |
| CUSIP | 52886X107 |
| Location | New York; U.S.A |
| Business Address | 345 Park Avenue |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.lexeotx.com |
| Phone | 212 547 9879 |
Lexeo Therapeutics, Key Financial Ratios
| Return On Equity | -0.85 | ||||
| Gross Profit | (74.09 M) | ||||
| EBITDA | (105.14 M) | ||||
| Net Income | (98.33 M) | ||||
| Book Value Per Share | 3.53 X |
Lexeo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lexeo Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Lexeo Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lexeo Therapeutics, competition to find correlations between indicators driving Lexeo Therapeutics,'s intrinsic value. More Info.Lexeo Therapeutics, Common is currently regarded as number one stock in return on equity category among its peers. It is rated second overall in return on asset category among its peers . At this time, Lexeo Therapeutics,'s Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexeo Therapeutics,'s earnings, one of the primary drivers of an investment's value.Lexeo Therapeutics, Systematic Risk
Lexeo Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lexeo Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Lexeo Therapeutics, correlated with the market. If Beta is less than 0 Lexeo Therapeutics, generally moves in the opposite direction as compared to the market. If Lexeo Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lexeo Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lexeo Therapeutics, is generally in the same direction as the market. If Beta > 1 Lexeo Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Lexeo Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexeo Therapeutics,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lexeo Therapeutics, growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Lexeo Therapeutics, March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lexeo Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lexeo Therapeutics, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lexeo Therapeutics, Common based on widely used predictive technical indicators. In general, we focus on analyzing Lexeo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lexeo Therapeutics,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 32.67 | |||
| Value At Risk | (9.38) | |||
| Potential Upside | 9.3 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.